PannTheraPi
Private Company
Funding information not available
Overview
PannTheraPi is a French biotech innovating in neurology with a novel approach targeting the pannexin 1 channel, a mechanism implicated in the root cause of several brain diseases. Its lead asset, PTI5803, has completed a positive Phase 1 trial and is preparing for Phase IIa, initially targeting a high-need pediatric orphan epileptic syndrome. The company is built on strong scientific co-founding expertise in neuroglial biology and epilepsy, positioning it to potentially address a broad range of neurological and psychiatric conditions with new chemical entities.
Technology Platform
Small molecule inhibitors selectively targeting the pathologically activated pannexin 1 (PANX1) channel, a mechanism implicated in the root cause of various neurological and psychiatric diseases.
Opportunities
Risk Factors
Competitive Landscape
The selective targeting of activated PANX1 is a first-in-class approach, potentially giving PannTheraPi a unique position. However, it may face indirect competition from other anti-inflammatory or neuroprotective mechanisms in development for epilepsy and neurology. The landscape for rare pediatric epilepsies includes other biotechs targeting specific genetic mutations.